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Abstract
Background: Vision health is recognized as a critical 
unmet need in North America. The ocular morbidity asso-
ciated with glaucoma results from increased intraocular 
pressure (IOP) and early detection is crucial for the man-
agement of glaucoma. Our objective was to find a diagnos-
tically accurate screening tool for intraocular hyperten-
sion that can be used in rural communities. We sought 
to validate the diagnostic accuracy of the iCare rebound 
tonometer against the gold standard Perkins applanation 
tonometer (PAT) in measuring IOP.
Methods: Patients from two rural communities in Ontario, 
Canada visiting their optometrists for routine appoint-
ments had their IOP measured by a non-contact tonom-
eter (NCT), an iCare rebound tonometer, and a Perkins 
applanation tonometer (PAT). Values of sensitivity, speci-
ficity, and likelihood ratios for a positive and negative 
result were calculated for the iCare and the NCT.
Results: Complete data was collected from 209 patients. 
Overall, the iCare tonometer had high levels of validity, as 
compared to the gold standard PAT. The iCare tonometer 
displayed excellent sensitivity of 98.3% (90–99%, 95% CI) 
and excellent negative likelihood ratio of 0.024 (0.0088–
0.066, 95% CI) which is useful for ruling out intraocular 
hypertension.
Conclusions: The iCare tonometer is a reasonably valid 
tool for detecting elevated IOP. Its ease of use, simplicity, 
and accessibility makes it a good screening tool to improve 
eye health in rural areas.
Keywords: glaucoma; iCare rebound tonometer; IOP; 
Perkins applanation tonometer; rural; screening.
Introduction
Glaucoma: an increasing problem
Open-angle glaucoma (OAG) affects approximately 
66.8 million people worldwide [1] and is a leading cause of 
blindness via irreversible optic nerve damage [2], second 
only to cataracts in many populations [3, 4]. In the US, 
OAG affects over 2.22 million individuals [5] and is the 
leading cause of blindness in African Americans [6]. Due 
to the rapidly aging population, the number with OAG will 
increase by 50% to 3.6 million in 2020 [5] with only half 
of these patients receiving the proper diagnosis and care 
[7, 8].
One study reports the rural prevalence of glaucoma to 
be 2.1% [9]. An estimated 4%–7% of people over 40 years 
old have elevated intra-ocular pressure (IOP) without 
detectable glaucomatous damage on standard tests [10]. 
Currently, the frequency of primary healthcare physicians 
asymptomatic glaucoma screening is uncertain in the US 
or elsewhere, although symptomatic glaucoma is often 
misdiagnosed [11, 12]. Primary care staff can be trained to 
screen for glaucoma [13].
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Need for rural eye care
Access to specialized care is a serious problem in most 
rural areas [14], which accounts for 19.3% of US population 
as of 2010 [14]. Although nearly 20% of Americans live in 
rural areas, only 9% of physicians practice in these com-
munities [14]. Vision health is recognized by US Depart-
ment of Health and Human Services as a critical unmet 
need, particularly in rural America with only about 20% 
of federally qualified community health centers provid-
ing eye care services [15]. If accurate, reliable, and readily 
available intraocular pressure screening instruments 
existed, teleophathalmology provides an opportunity to 
improve eye health in rural settings worldwide [16, 17].
Screening for glaucoma
In October 2013, the US Preventive Services Task Force 
concluded that the current evidence is insufficient to 
recommend screening for POAG in adults [18]. While 
population-based glaucoma screening is currently not 
cost-effective [19], glaucoma screening may be cost effec-
tive if directed at high-risk individuals [20]. The American 
Academy of Ophthalmology [21], the Veterans Administra-
tion [22], and the National Institutes of Health [23] sup-
ports early glaucoma detection and treatment. Medicare 
covers regular glaucoma screenings [23] for high-risk indi-
viduals [24] (Table 1). The most practical method for wide-
spread screening of targeted populations is to identify risk 
factors, assess IOP and perform a dilated-eye examination 
with attention to the optic disk [25].
The ocular morbidity associated with glaucoma results 
from increased IOP [26]. Ocular hypertension is also an 
important risk factor for the progression to glaucoma [10]. 
The Early Manifest Glaucoma Trial identified ocular hyper-
tension to have a hazard ratio of 1.67 (1.19–2.35, 95% CI) for 
glaucoma progression [10]. Early detection of intraocular 
hypertension is crucial for the management of glaucoma 
[27]. Although elevated IOP is not the only risk factor for 
progressive optic nerve damage, it is the most amenable 
Table 1: Risk factors for glaucoma [24].
Risk factors
Age  > 60 years
Age  > 40 years (African Americans)
Family history of glaucoma
Extreme myopia
Diabetes mellitus
to intervention [28]. It is important to treat elevated IOP in 
higher-risk individuals for two reasons: it can effectively 
delay or prevent glaucomatous eye damage [27]; and the 
cost of treatment increases with the progression of the 
disease [29].
Measuring IOP
The Goldmann applanation tonometry (GAT) is currently 
considered a gold standard in tonometry, the measure-
ment of IOP [30] (Figure  1). The Perkins applanation 
tonometer (PAT) is a handheld device (Figure 1) that is 
considered the handheld Goldmann tonometer [31]. The 
PAT is useful in patients who are obese, bedridden, and 
difficult to posture onto the slit lamp to be assessed by the 
GAT [32]. Both GAT and PAT have various drawbacks such 
as the need for topical anesthesia of the eye and operation 
by an experienced user [31]. Corneal factors such as curva-
ture, astigmatism, central corneal thickness also affect the 
accuracy of applanation tonometers [31]. The non-contact 
tonometer (NCT) (Figure 1) is often used as a screening tool 
to measure IOP, instead of using the GAT. While the NCT 
is quick and non-invasive [31, 33], it is not portable and 
costs range from $5000 to $22,000 depending on the type 
of machine. Thus, access to NCTs outside of professional 
eye care services is uncommon. Other readily available 
glaucoma screening options like the pinhole visual acuity 
test have been described, but are not generally accepted 
as it does not result in increased glaucoma referrals to 
eye care professionals [34]. More expensive, less available 
screening tools include time-domain and spectral-domain 
optical coherence tomography [35].
The iCare tonometer is a relatively new IOP measur-
ing device that uses the principle of rebound tonometry 
[36] (Figure 1). Rebound tonometry is a relatively new 
method based on analyzing the motion parameters of 
a bouncing probe colliding with the cornea [37]. Probe 
deceleration is lower at low IOP and, consequently, the 
higher the IOP, the shorter the duration of the impact 
[38]. Unlike the GAT, the iCare rebound tonometer is 
quick to use, easily portable, does not require the use 
of anesthetic eye drops, and can be used by an opera-
tor without specialized training [36]. However, the iCare 
tonometer can only be used on patients in the seated 
position [36]. In many rural clinics and hospitals, 
neither GAT nor PAT is available, either due to unfa-
miliarity with the device or reluctance to use anesthetic 
eye drops (which may be painful). Furthermore, the 
iCare tonometer has reasonable agreement and repeat-
ability in comparison to GAT, even when the GAT was 
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used by experienced users  [39–41]. As the GAT and PAT 
requires training and experience to achieve proficiency, 
the measurements collected by an inexperienced user 
may prone to variation and error [39]. Thus, access to a 
simple, reliable, and accurate instrument is desirable in 
order to obtain a rapid assessment of IOP. The objective 
of this study was to quantify the accuracy of the iCare 
tonometer in the measurement of IOP using PAT as the 
criterion standard in rural eye clinic patients.
Materials and methods
Patients in one of two rural optometric offices in Huron County, 
Ontario, Canada were invited to participate in our study by one of 
two research students during the month of July in 2013. The two com-
munities included in our study had populations of 3000 and 8000. 
Furthermore, they are over 100 km from a level one trauma center 
and both communities are deemed “rural” by the Ontario Govern-
ment using a rurality index Ontario (RIO) score [42].
The sample size was calculated [43] based on a sensitivity of 0.95, 
specificity of 0.9, and confidence interval of 95%. The reported preva-
lence of OAG was estimated to be 2.1% in a white rural population [9]. 
A sample size of 142 participants was determined to be necessary to 
confirm iCare accuracy of 95% sensitivity, specificity 90% with con-
fidence intervals of ±5% with a sample size of 142 participants, if the 
prevalence of OAG was 2.1%.
Written and verbal consent were collected before IOP meas-
urements were collected. Exclusion criteria included age  < 18 years, 
severe corneal abnormalities, recent intraocular surgery, and active 
ocular infective disease. As there were no translational services avail-
able, those who do not speak, read or write English were excluded 
as well.
IOP measurement by NCT
The routine patient assessment involved an IOP measurement in 
both eyes using NCT, iCare tonometer, and PAT, respectively. First, 
IOP was measured using NCT by one of two optometric assistants. 
Patients were instructed to remove contact lenses and be relaxed. 
Patients were positioned so that their forehead contacted the head-
rest straight on and the canthus marks on the sides of the instrument 
were level with the patients’ eyes. Patients were then instructed to 
blink several times then hold their eyes open immediately before the 
measure response button was clicked. Each eye was measured sepa-




Figure 1: IOP measuring devices.
(A) Non-contact tonometer. (B) Goldmann applanation tonometer mounted on a slit lamp. (C) Perkins applanation tonometer. (D) iCare 
rebound tonometer.
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IOP measurement by iCare
Next, IOP was measured using an iCare tonometer by one of two 
trained research students who were masked to the IOP measure-
ments by NCT. The research students were trained in the use of the 
iCare tonometer by a representative from Topcon Canada. The train-
ing session lasted 30 min and the students were shown the proper 
tonometer technique, how to adjust the calibrations depending on 
each patient’s needs, and how to change the disposable probe. Each 
student took one set of IOP measurements using the iCare tonom-
eter during the training session. Two instructional videos totalling 
3 min in length were also shown to the students. These videos can be 
found on http://icare-usa.com/icare-tonometer/videos/. IOP meas-
urements using the iCare device were taken between 1 and 10  min 
after measurements were taken using the NCT.
IOP measurement by PAT
Lastly, IOP was measured by one of four optometrists who were 
masked to both previous measures of IOP. Proparacaine hydrochloride 
ophthalmic solution (0.5%) was used as a topical anesthetic in each 
eye. Each optometrist waited between 2 and 5 min after the anesthetic 
was given before the IOP of each eye was measured using the PAT.
Statistical measures of performance
The criteria used to define ocular hypertension during the past 
10 years have been highly variable, with a mode value of 22 mmHg 
[44]. To establish accuracy values, an IOP of 22 mmHg or greater was 
used to designate ocular hypertension [10] for both the gold standard 
(PAT) and test (iCare and NCT). Values of sensitivity, specificity, and 
likelihood ratios for a positive and negative result (LR+, LR–, respec-
tively) were calculated for each test measurement. Interval likelihood 
ratios [45] were computed based on the sensitivity and specificity of 
each test. These values were used to assess the overall accuracy and 
validity against the gold standard measurement. A receiver operating 
characteristic (ROC) plot was created for each measurement and all 
possible cut-off values. The area under the curve (AUC) was used as 
a summary measure of test accuracy (where an AUC of 0.5 indicates 
an uninformative test, and an AUC of 1.0 indicates a perfect test [46]). 
The Student’s t-test was used to calculate any p-value to evaluate sta-
tistical significance.
The conduct and reporting of this study adhered to the stand-
ards for reporting of diagnostic accuracy (STARD) criteria [47] except 
where noted. All statistical analyses were conducted using SAS 9.3. 
Written and verbal informed consent was obtained from each patient 
prior to his or her participation. No incentives or compensation 
were given to participate in this study. This research study proposal 
was reviewed and approved by the University of Western Ontario’s 
Research Ethics Board.
Results
A total of 232 patients from two rural optometric offices 
were approached and 230 patients consented to par-
ticipate in this study (Figure  2). Of these patients, 21 
patients did not have complete data for the gold stand-
ard measurement and were subsequently excluded from 
the final analyses. The patients who were excluded did 
not differ from the included patients in any significant 
way. Patients with complete data had an average age of 
63.3 years and approximately 55% of the patients were 
female (Table 1). There were 114 women (mean age 
63.7±18.4 years) and 95 men (mean age 62.9±17.7 years) 
(Table 2).
We evaluated the sensitivity and specificity of the 
iCare tonometer and NCT by constructing 2 × 2 tables using 
IOPs of 22  mmHg or higher as measured by the PAT to 
define elevated IOP. The iCare measured 15 patients with 
IOP  ≥ 22  mmHg and 194 patients with IOP  < 22  mmHg, 
respectively; 10 were false-positives and two were false-neg-
atives. The NCT measured 21 patients with IOP  ≥ 22 mmHg 




Consented and enrolled n=230
PAT IOP ≥22 mmHg in at
least one eye n=10
iCare IOP ≥22 mmHg in at
least one eye n=15
NCT IOP ≥22 mmHg in at





Figure 2: Flow diagram for patient enrolment.
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and 180 patients with IOP  < 22 mmHg, respectively; 15 were 
false-positives and five were false-negatives.
The sensitivity of iCare is 98% (90–99%, 95% CI) and 
the specificity is 79% (74–85%, 95% CI) (Table 3). The LR+ 
and LR– of the iCare were found to be 4.9 (4.6–5.3, 95% CI) 
and 0.024 (0.0088–0.066, 95% CI), respectively (Table 3). 
The AUC for the iCare measurements was 0.922 (0.819–
0.955, 95% CI) (Table 3, Figure 3).
The sensitivity of the NCT is 90.8% (90–99%, 95% CI) 
and the specificity of 66.7% (90–99%, 95% CI) (Table 4). 
Table 3: iCare tonometer diagnostic accuracy.
Measures of validity   Value
Sensitivity,% (95% CI)   98 (90–99)
Specificity,% (95% CI)   79 (74–85)
LR+ (95% CI)   4.9 (4.6–5.3)
LR– (95% CI)   0.024 (0.0088–0.066)

















iCare and NCT ROC Curves
iCare
NCT
Figure 3: ROC curves for iCare and NCT. AUC (95% CI): iCare 0.922 
(0.819–0.955); NCT 0.904 (0.770–0.938).
n = 209 patients who had complete IOP measurements by the NCT, 
iCare, and PAT.
Table 4: NCT diagnostic accuracy.
Measures of validity   Value
Sensitivity,% (95% CI)  98 (87–99)
Specificity,% (95% CI)   67 (61–73)
LR+ (95% CI)   4.0 (3.6–4.2)
LR– (95% CI)   0.033 (0.0088–0.13)
AUC (95% CI)   0.904 (0.770–0.938)
Table 5: Interval likelihood ratios.











The LR+ and LR– of the NCT is 4.0 (3.6–4.2, 95% CI) and 
0.033 (0.0088–0.13, 95% CI), respectively (Table 4). The 
AUC for the NCT measurements was 0.904 (0.770–0.938, 
95% CI) (Table 4, Figure 3).
The interval likelihood ratio (iLR) for the iCare is 0.080 
(for IOP  < 19 mmHg), 4.1 (for IOP 19–22 mmHg), 69 (for IOP 
22–25 mmHg), and ∞ (extremely high) (for IOP  > 25 mmHg) 
(Table 5). The iLR for the NCT is 0.00 (for IOP  < 19 mmHg), 
1.4 (for IOP 19–22 mmHg), 4.5 (for IOP 22–25 mmHg), and 
43 (for IOP  > 25 mmHg) (Table 5).
There were 37 patients who had significant discrepan-
cies in IOP measurement ( > 3  mmHg) between the iCare 
and the PAT. The maximum discrepancy between the 
iCare and PAT measurements was 11.1 mmHg. Of these 37 
patients, seven had ocular hypertension as reported by 
the iCare only and two had ocular hypertension reported 
by the PAT only.




Overall, the iCare tonometer and NCT tonometer were 
reasonably accurate compared to the gold standard 
Table 2: Patient characteristics.






Age, years (mean)   63.3
Male, year (mean)   62.9
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PAT. Both the iCare tonometer and NCT displayed excel-
lent sensitivity of 98.3% (90–99%, 95% CI) and 90.8% 
(90–99%, 95% CI), respectively. Our results demonstrate 
that the iCare rebound tonometer is an accurate instru-
ment to screen for intraocular hypertension. Our data 
suggest that iCare tonometer slightly overestimates the 
IOP values compared to the PAT IOP values. However, 
the overestimation by the iCare does not appear to be 
statistically significant (p = 0.190). The overestimation by 
the iCare was 0.217±2.40  mmHg (mean bias±STD) with 
95% CI±0.325  mmHg. Similarly, the NCT also overesti-
mates the IOP values compared to the PAT IOP values. 
However, the overestimation by the NCT is statisti-
cally significant (p < 0.001). The overestimation by the 
NCT was: 1.22±1.94  mmHg (mean bias±STD) with 95% 
CI±0.278 mmHg.
The iCare tonometer is useful for ruling out intraocu-
lar hypertension because of its very good negative likeli-
hood ratio. LR+ describes how probability of disease shifts 
when the finding is present, and LR– describes the prob-
ability shift of an absent finding [48]. The closer the LR– is 
to zero, the more strongly an absent finding decreases the 
likelihood of disease [48]. The LR– for the iCare tonometer 
is 0.024 (0.0088–0.066 95% CI) (Table 3). For instance, if 
a rural patient with a 5% probability of elevated IOP has 
an iCare reading  < 22 mmHg, he or she now has a 0.12% 
chance of having an elevated IOP as measured by PAT 
(Table 3). Specifically, iLR is the corresponding likelihood 
ratio for each IOP interval (Table 5). These iLRs adjust the 
probability of having an elevated IOP as measured by the 
PAT. Thus, a normal IOP as measured by the iCare tonom-
eter drastically reduces the probability of ocular hyperten-
sion as measured by the PAT.
Early-stage glaucoma
One of the most common causes of malpractice claims 
against optometrists in the US is misdiagnosed OAG [49]. 
Chronic glaucoma is difficult to recognize in its early 
stages due to its asymptomatic nature [7, 8]. Up to 50% 
of individuals with glaucoma in the industrialized world 
are unaware and not receiving care [7, 8]. Many glaucoma 
patients are only identified when their glaucoma has pro-
gressed to a moderate or severe stage [50]. Recognizing 
ocular hypertension is important because treatment to 
lower IOP may delay progression of visual field deficits in 
some asymptomatic individuals with early OAG [12]. The 
Early Manifest Glaucoma Trial found that immediate treat-
ment of people who have early-stage glaucoma can delay 
progression of the disease [51]. The Ocular Hypertension 
Treatment Study found that topical ocular hypotensive 
medication was effective in delaying or preventing onset 
of OAG in individuals with elevated IOP [10]. Thus, it is 
beneficial to have an effective tool to evaluate the pres-
ence of ocular hypertension so that a timely referral to an 
ophthalmologist or optometrist can be made.
Limitations
Limitations of our study included: convenience sampling; 
spectrum bias; no assessment of reliability; and lack of 
patient demographic information (such as race). In the 
setting of an eye clinic, there is an inherent bias towards 
patients who are more likely to have ocular disease. 
To account for this, this study should be replicated in a 
primary care and ED setting, where patients most likely 
to benefit from this new technology are likely to present 
prior to referral to an eye clinic. Since glaucoma is a spec-
trum of disease and non-disease, our study was subject 
to spectrum bias. Sensitivity of a diagnostic test depends 
on the spectrum of disease [52]. Thus, spectrum bias likely 
inflated the sensitivity of the iCare tonometer [52]. Another 
limitation was that it was unknown how many individuals 
in our study were known to have glaucoma. Furthermore, 
there was an under-representation of adults aged   ≤  64 
since routine eye exams are not covered by OHIP (Ontario 
Health Insurance Plan) for adults between and including 
20 and 64 years of age [53].
It is well known that tonometry results are influenced 
by many other factors such as time of the day [54], central 
corneal thickness (CCT) [55–57], and patient position [55]. 
The influence of CCT on IOP determination is based on the 
assumption that thicker corneas are not as deformable 
as thinner corneas. This would theoretically result in a 
thicker cornea recording an artificially high IOP. Whereas 
some studies on rebound tonometry reported a correla-
tion with CCT [56], others did not detect any correlation 
between CCT and IOP values [57]. For a more comprehen-
sive analysis, IOPs should be recorded with their corre-
sponding CCTs.
Conclusions
The iCare tonometer is highly sensitive in detecting ele-
vated IOP as compared to the handheld gold standard 
PAT. The iCare tonometer is also useful for ruling out glau-
coma because of its very good negative likelihood ratio. 
Its simplicity and portability makes it appropriate for use 
in rural community clinics for the assessment of elevated 
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IOP, which – if treated – may delay or prevent the onset 
of OAG. Therefore, this iCare tonometer could reasonably 
be used by clinicians as a suitable substitute for the gold 
standard Perkins tonometer to assess elevated IOP in the 
rural clinic or emergency department.
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